Molecular and Cellular Biochemistry

, Volume 321, Issue 1–2, pp 9–22 | Cite as

Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction

  • Arivazhagan Palaniyappan
  • Richard R. E. Uwiera
  • Halliday Idikio
  • Bodh I. JugduttEmail author


We determined effects of the vasopeptidase inhibitor (VPI) omapatrilat and angiotensin II type 1 receptor (AT1R) blocker (ARB) candesartan in rats during healing between day-2 and day-21 after reperfused myocardial infarction (RMI) on left ventricular (LV) remodeling and function, and regional matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP (TIMP)-3, inducible-nitric-oxide-synthase (iNOS), oxidant-generating myeloperoxidase (MPO), and cytokines tumor-necrosis-factor (TNF)-α, interleukin (IL)-6 and IL-10, and transforming-growth-factor (TGF)-β1, and collagens. Compared to RMI-placebo, both agents reversed adverse LV remodeling and systolic and diastolic dysfunction, improved collagen remodeling, and normalized MMP-9 (activity, protein, and mRNA), TIMP-3 (protein and mRNA), and iNOS, MPO, TNF-α, IL-6, and TGF-β1 proteins, and improved MMP-9/TIMP-3 balance and IL-10 levels in previously ischemic zones. The results suggest that modulation of matrix proteases, oxidants, cytokines, and NOSs with omapatrilat and candesartan contribute to reversal of adverse collagen and LV remodeling and attenuation of LV dysfunction during healing after RMI.


Vasopeptidase inhibitor Angiotensin II type 1 receptor blocker Extracellular matrix Myeloperoxidase Cytokines Ventricular remodeling Reperfused myocardial infarction 



This work was supported in part by a grant from the Heart and Stroke Foundation of Canada. We thank Astra Pharma Inc. (Mississauga, Ontario, Canada) and Bristol-Myers Squibb Co. (Saint-Laurent, Quebec, Canada) for supplying candesartan and omapatrilat, respectively. We are indebted to C. Jugdutt for manuscript preparation and Mr. Vijayan Menon for computer support.

Disclosure: Gift of drugs from Industry and small operating grant from HSFC.


  1. 1.
    Jugdutt BI (2003) Ventricular remodeling post-infarction and the extracellular collagen matrix. When is enough enough? Circulation 108:1395–1403. doi: 10.1161/01.CIR.0000085658.98621.49 PubMedCrossRefGoogle Scholar
  2. 2.
    Jugdutt BI (2003) Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 3:1–30. doi: 10.2174/1568006033337276 PubMedCrossRefGoogle Scholar
  3. 3.
    Sawicki G, Menon V, Jugdutt BI (2004) Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail 10:442–449. doi: 10.1016/j.cardfail.2004.01.012 PubMedCrossRefGoogle Scholar
  4. 4.
    Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al (2002) Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106:2351–2357. doi: 10.1161/01.CIR.0000036014.90197.FA PubMedCrossRefGoogle Scholar
  5. 5.
    Jugdutt BI (2006) Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction. J Card Fail 12:73–76. doi: 10.1016/j.cardfail.2005.10.001 PubMedCrossRefGoogle Scholar
  6. 6.
    Jugdutt BI (2002) Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev 7:391–405. doi: 10.1023/A:1020718619155 PubMedCrossRefGoogle Scholar
  7. 7.
    Sawicki G, Jugdutt BI (2007) Valsartan reverses post-translational modifications of the δ-subunit of ATP synthase during in vivo canine reperfused myocardial infarction. Proteomics 42:2100–2110. doi: 10.1002/pmic.200601022 CrossRefGoogle Scholar
  8. 8.
    Vasilyev N, Williams T, Brennan ML et al (2005) Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112:2812–2820. doi: 10.1161/CIRCULATIONAHA.105.542340 PubMedCrossRefGoogle Scholar
  9. 9.
    Yasmin W, Strynadka KD, Schulz R (1997) Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 33:422–432. doi: 10.1016/S0008-6363(96)00254-4 PubMedCrossRefGoogle Scholar
  10. 10.
    Mungrue IN, Husain M, Stewart DJ (2002) The role of NOS in heart failure: lessons from the murine genetic models. Heart Fail Rev 7:407–422. doi: 10.1023/A:1020762401408 PubMedCrossRefGoogle Scholar
  11. 11.
    Jugdutt BI (2006) Valsartan in the treatment of heart attack survivors. J Vasc Health Risk Manag 2:125–138. doi: 10.2147/vhrm.2006.2.2.125 CrossRefGoogle Scholar
  12. 12.
    Granger CB, McMurray JJV, Yusuf S, CHARM Investigators Committees et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362:772–776. doi: 10.1016/S0140-6736(03)14284-5 PubMedCrossRefGoogle Scholar
  13. 13.
    Jugdutt BI, Idikio H, Uwiera RER (2007) Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction. Mol Cell Biochem 303:27–38. doi: 10.1007/s11010-007-9452-3 PubMedCrossRefGoogle Scholar
  14. 14.
    Burnett JC Jr (1999) Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 17:S37–S43Google Scholar
  15. 15.
    Burrell LM, Farina NK, Balding LC, Johnston CI (2000) Beneficial renal and cardiac effects of vasopeptidase inhibition with S31402 in heart failure. Hypertension 36:1105–1111PubMedGoogle Scholar
  16. 16.
    Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T (1998) Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 31:116–125. doi: 10.1097/00005344-199801000-00017 PubMedCrossRefGoogle Scholar
  17. 17.
    Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM (1999) Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34:782–790. doi: 10.1097/00005344-199912000-00003 PubMedCrossRefGoogle Scholar
  18. 18.
    Xu J, Carretero OA, Liu YH et al (2004) Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10:83–89PubMedGoogle Scholar
  19. 19.
    Packer M, Califf RM, Konstam MA et al (2002) Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106:920–926. doi: 10.1161/01.CIR.0000029801.86489.50 PubMedCrossRefGoogle Scholar
  20. 20.
    Rouleau JL, Pfeffer MA, Stewart DJ et al (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356:615–620. doi: 10.1016/S0140-6736(00)02602-7 PubMedCrossRefGoogle Scholar
  21. 21.
    Lapointe N, Blais C Jr, Adam A et al (2002) Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J Am Coll Cardiol 39:1692–1698. doi: 10.1016/S0735-1097(02)01837-5 PubMedCrossRefGoogle Scholar
  22. 22.
    Solomon SD, Skali H, Bourgoun M et al (2005) Effect of angiotensin-converting-enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE) echocardiographic study. Am Heart J 150:257–262. doi: 10.1016/j.ahj.2004.09.056 PubMedCrossRefGoogle Scholar
  23. 23.
    Jugdutt BI, Menon V (2004) AT2 receptor and apoptosis during AT1 receptor blockade in reperfused myocardial infarction in the rat. Mol Cell Biochem 262:203–214. doi: 10.1023/B:MCBI.0000038236.59905.8b PubMedCrossRefGoogle Scholar
  24. 24.
    Jugdutt BI, Menon V (2004) Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction. J Card Fail 10:74–82. doi: 10.1016/S1071-9164(03)00584-0 PubMedCrossRefGoogle Scholar
  25. 25.
    Reffelmann T, Hale SL, Dow JS, Kloner RA (2003) No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation 108:2911–2917. doi: 10.1161/01.CIR.0000101917.80668.E1 PubMedCrossRefGoogle Scholar
  26. 26.
    Matsumura K, Jeremy RW, Schaper J, Becker LC (1998) Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 97:795–804PubMedGoogle Scholar
  27. 27.
    Jugdutt BI, Joljart MJ, Khan MI (1996) Rate of collagen deposition during healing after myocardial infarction in the rat and dog models: mechanistic insights into ventricular remodeling. Circulation 94:94–101PubMedGoogle Scholar
  28. 28.
    Jugdutt BI, Khan MI, Jugdutt SJ, Blinston GE (1995) Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate. Circulation 92:926–934PubMedGoogle Scholar
  29. 29.
    Watson EL, Sheth M, Denyer RF, Dostal DE (2004) Baseline echocardiographic values for adult male rats. J Am Soc Echocardiogr 17:161–167. doi: 10.1016/j.echo.2003.10.010 PubMedCrossRefGoogle Scholar
  30. 30.
    Goldman S, Shalev E (2006) Difference in progesterone-receptor isoforms ratio between early and late first-trimester human trophoblast is associated with differential cell invasion and matrix metalloproteinase 2 expression. Biol Reprod 74:13–22. doi: 10.1095/biolreprod.105.044925 PubMedCrossRefGoogle Scholar
  31. 31.
    Mullane KM, Kraemer MR, Smith B (1985) Myeloperoxidase activity as a quantitative of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:156–167. doi: 10.1016/0160-5402(85)90029-4 CrossRefGoogle Scholar
  32. 32.
    Frangiogiannis NG, Smith CW, Entman ML (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53:31–47. doi: 10.1016/S0008-6363(01)00434-5 CrossRefGoogle Scholar
  33. 33.
    Wang D, Yang XP, Liu YH, Carretero OA, LaPointe MC (1999) Reduction of myocardial infarct size by inhibition of inducible nitric oxide synthase. Am J Hypertens 12(2 Pt 1):174–182. doi: 10.1016/S0895-7061(98)00235-0 PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang X, Recchia FA, Bernstein R, Xu X, Nasjletti A, Hintze TH (1999) Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment of heart failure. J Pharmacol Exp Ther 288:742–751PubMedGoogle Scholar
  35. 35.
    Wang CH, Leung N, Lapointe N et al (2003) Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in zucker fatty rats. Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 107:1923–1929. doi: 10.1161/01.CIR.0000062646.09566.CC PubMedCrossRefGoogle Scholar
  36. 36.
    Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr (2008) Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma J 100:327–332CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Arivazhagan Palaniyappan
    • 1
  • Richard R. E. Uwiera
    • 2
  • Halliday Idikio
    • 3
  • Bodh I. Jugdutt
    • 1
    • 4
    Email author
  1. 1.Cardiovascular Research Group, Faculty of MedicineUniversity of AlbertaEdmontonCanada
  2. 2.Health Sciences Laboratory Animal Services, Faculty of MedicineUniversity of AlbertaEdmontonCanada
  3. 3.Department of Pathology and Laboratory Medicine, Faculty of MedicineUniversity of AlbertaEdmontonCanada
  4. 4.2C2 Walter C. Mackenzie, Cardiology Division of the Department of Medicine, Faculty of MedicineUniversity of AlbertaEdmontonCanada

Personalised recommendations